



CPC of America, Inc.

6336 17th Street Circle East
Sarasota Florida 34243
(941) 727-4370
FAX (941) 727-4371
www.cpga2000.com
Symbol: CPCF

April 10, 2008

To our Stockholders and Friends:

The Company is pleased to announce progress through cooperation with the FDA, supported by assistance from additional consultants, and advisors. A recent meeting with FDA representatives and subsequent developments the past several weeks are expected to produce timely resumption of clinical studies in the United States (U.S.). It was apparent to our team members who attended the meeting that a philosophical difference of beliefs surrounds application of a “significant risk” definition determination even though three separate Investigational Review Boards (one in U.S., 2 in Canada) in 2006 and 2007 determined that any risk to subjects was “non significant”. The Company believes that this difference among the parties was due to a lack of understanding and communication about the application of the MedClose™ VCS technology. Prior to the start of clinical investigations, this technology had been described as a “vascular closure device.” In reality through clinical investigation, the MedClose™ VCS is a crossover between a vascular closure device (invasive) which “closes” the opening from the inside of femoral artery and a wound “cover” device (non invasive) which “closes” openings from the outer surface of the artery wall. The MedClose™ VCS as an extra vascular closure system (closes outside of the vascular artery) utilizes a biological sealant that creates an “elastic coagulum” that is easily absorbed by the body, typically within 10 to 14 days. As a reminder in regulatory terms, this crossover technology is not an implant; it does not support or sustain life; it does not diagnose, cure, mitigate, treat or prevent disease; and does not present the potential for serious risk to health, safety, or welfare of a subject.

A recent study released in March, 2008 led by study leader, Dr. Michael Kutcher, Wake Forest University in Winston-Salem, N.C. supports that even application of Angioplasty is safe without back up open heart surgeon or facilities. Thus the Company will continue to demonstrate, educate, inform and debate, as such, the features of the MedClose™ VCS medical device as to its design, use, primary mode of action and thus its safety and effectiveness. Moreover, in both U.S. and Canadian Clinical Trials there were no reported safety issues even in the event of a device failure occurrence; and, the gold standard of manual compression was applied without incident. This performance cannot be claimed for competing FDA approved commercial vascular closure devices. The expectations of safety, no residue left in the femoral artery, patient comfort, less utilization of cath lab procedures room, cath lab staffing and nursing staffing are continuously being validated. The Company fully expects, based upon recent outcomes and planning performance by the new development/commercial team, to resume clinical trials during 2008 in the U.S. and Canada as well as our continuing preparation and eventual submission of applications for commercial availability in Canada, other foreign countries, and the US.

The Company is also pleased to report that its additional capital requirements in the amount of \$1,743,020.00 have been obtained at present through the Series E Private Placement Memorandum. The Company will continue to work diligently to raise the balance of funds to achieve our goals and to insure the success of this development and commercialization of this exciting crossover technology of the MedClose™ VCS. I am sure you will agree as well.

In conclusion, while the overall domestic and world markets have been tumultuous for everyone since Q3 of 2007 to current, we thank you for your continued support of the Company.

Very truly yours,

/s/ Rod A. Shipman
Rod A. Shipman, Chief Executive Officer